PRF and PRP Uses: Conditions and Medical Specialties
Which conditions and medical specialties use PRF versus PRP most often?
The split between these two preparations isn't a matter of taste, and once you see the reason you can predict which one a clinic reaches for before you walk in the door. One comes out of the centrifuge as a liquid that travels down a needle, the other comes out as a clot you can press into a hole, and that single physical fact decided which specialties adopted which.
| Where It's Used | Platelet Rich Plasma | Platelet Rich Fibrin |
|---|---|---|
| Dominant specialties | Orthopedics, sports medicine, hair restoration | Dentistry, periodontics, oral and maxillofacial surgery |
| How it's delivered | Injected into joints, tendons and scalp | Packed, folded or laid into a surgical site |
| Signature cases | Knee osteoarthritis, tennis elbow, pattern hair loss | Extraction sockets, sinus lifts, intrabony defects |
| Shared ground in aesthetics | Microneedling and broad facial or scalp injection | Tear trough, nasolabial folds, hand volumising |
| Role in wound care | Activated into a gel and spread on the bed | Cut into a membrane and laid in the bed |
Platelet rich plasma dominates orthopedics, sports medicine and hair restoration because it stays liquid and injectable, while platelet rich fibrin dominates dentistry, periodontics and oral surgery because it clots within minutes into a membrane that can be packed into a defect.
Which orthopedic and sports medicine injuries are treated with platelet rich plasma rather than a fibrin clot?
Orthopedics and sports medicine burn through more plasma than every other field combined, and the reason is plumbing before it's biology. You can't push a clot down a needle into a closed knee under ultrasound guidance, so the fluid preparation wins by default. What actually varies inside the specialty isn't the product, it's how well the evidence holds up as you move from one joint to the next.
Leukocyte poor plasma is preferred for intra-articular use because white cells drive catabolic and inflammatory signalling inside a synovial joint, while leukocyte rich preparations are still used for tendinopathy outside the joint, typically one to three injections spaced two to four weeks apart.
Why did oral and maxillofacial surgery become the earliest home for fibrin based concentrates?
Most people assume dentistry got there first because dentists like new toys. It's the opposite. An extraction socket, a sinus window or a periodontal defect is an open space that needs filling and covering, and a fibrin clot is a physical object you can compress into a membrane, cut, fold and tuck under a flap.
- Single short spin: Plain tubes, eight to twelve minutes at low speed, no additive to source or justify.
- Core indications: Ridge preservation, sinus floor elevation, guided bone regeneration, intrabony defects, root coverage, jaw osteonecrosis.
- Measured gains: Around an extra millimetre of clinical attachment gain over open flap debridement alone.
- Hard ceiling: The clot resorbs in roughly two weeks and adds no structural rigidity.
Fibrin took hold in dental practice because it's drawn into plain tubes with no anticoagulant and spun once for roughly eight to twelve minutes, yielding a fully autologous clot that can be pressed into a membrane, plugged into a socket, or minced with graft particles into a mouldable mass.
How do dermatology and aesthetic clinics divide the two preparations across facial procedures?
Aesthetic dermatology is the one field using both in real volume, and the good clinics stopped arguing about which is better years ago. They just gave them different jobs. Which one your face needs comes down to whether you're treating a broad surface or filling one specific hollow.
Aesthetic clinics assign plasma to broad surface work like microneedling and superficial injection and reserve the fibrin gel for volumising the tear trough and similar hollows, where a matrix that degrades over roughly two weeks avoids the Tyndall effect and long lasting malar oedema that follow hyaluronic acid in that region.
What drives the choice between the two inside hair restoration protocols?
Hair restoration belongs to plasma by history, not by any proven biological win. Every trial worth quoting and every standard protocol you'll be offered in a consultation was built on the liquid preparation, so that's what a clinic reaches for without thinking. The fibrin argument is about release time, and it costs the clinician something at the chairside.
| Protocol Factor | Liquid Plasma | Injectable Fibrin |
|---|---|---|
| Evidence base | Randomised trials and meta-analyses in pattern loss | Few, small, short head to head trials |
| Session pace | Unhurried; stays fluid across the whole scalp | Working window of roughly fifteen to twenty minutes |
| Typical schedule | Monthly for three or four sessions, then every three to six months | Longer intervals proposed, not yet established |
| Reported effect | Higher density versus placebo; no proven change in hair thickness | Possible edge in durability, not a clear win |
Standard plasma protocols for androgenetic alopecia run monthly for three or four sessions and then every three to six months for maintenance, and they show meaningful increases in hair density against placebo without any demonstrated effect on individual hair thickness.
Which biological differences between the two preparations actually determine specialty preference?
Everything downstream follows from one decision made in the first ten seconds, at the tube. Put an anticoagulant in and you've got a liquid you can inject all afternoon; leave it out and you've got a clot inside minutes. Every specialty preference you've read about above is really just that one choice playing itself out.
- The draw: Citrate binds calcium and blocks the coagulation cascade for plasma, while plain tubes let clotting start the second blood hits the wall.
- The spin: Plasma usually takes a two stage or higher speed spin; fibrin takes one low speed spin of about eight to twelve minutes.
- The matrix: Dropping the centrifugal force leaves a looser, more cell rich mesh with more leukocytes and higher measured growth factor release.
- The release: Activated plasma dumps most of its growth factors in the first hour, while the fibrin mesh lets them out over days.
- The handoff: A clot can't go through a needle into a knee, and a liquid can't be tucked under a periodontal flap.
Activated plasma releases the great majority of its stored growth factors within the first hour, while a fibrin matrix elutes transforming growth factor beta, platelet derived growth factor and vascular endothelial growth factor gradually over seven to fourteen days and doubles as a resorbable scaffold that cells migrate into.
Where do wound care, podiatry and vascular clinics fit into platelet concentrate practice?
Wound care flips the usual rule on its head. Here the concentrate gets laid onto tissue instead of injected into it, so the clot's habit of holding its shape stops being a limitation and becomes the whole point. It's also the one corner of this field where somebody other than you occasionally pays the bill.
- Primary targets: Non healing diabetic foot ulcers, then venous leg ulcers, pressure injuries and post surgical dehiscences.
- Delivery: A fibrin membrane cut to size, or a plasma gel spread across the debrided bed.
- Coverage: The only indication where third party payment is at all common.
- Stop signs: Active infection, critical limb ischaemia, exposed bone or hardware, underlying malignancy.
Chronic wound protocols reapply the concentrate weekly alongside standard offloading, debridement and compression rather than in place of them, and chronic wound products are the only platelet concentrate use with any common third party coverage.
How do cost, anticoagulant rules and reimbursement shape which specialty adopts which preparation?
Follow the money and the specialty split stops looking clinical at all. A fibrin workflow costs a solo dental practice pocket change per case, while plasma workflows run on proprietary kits priced for a clinic charging several hundred to over a thousand dollars an injection. Since patients almost always pay out of their own pocket, that gap quietly decided who built a business around which product.
| Cost Factor | Fibrin Workflow | Plasma Workflow |
|---|---|---|
| Consumables per case | Low tens of dollars | Roughly fifty to several hundred dollars |
| Equipment | One centrifuge, plain tubes, a compression box | Proprietary single use kits and closed systems |
| Who pays | The patient, outside a narrow band of wound products | The patient; most payers still call it investigational |
| Paperwork | No anticoagulant to source or account for | An additive in the preparation to document |
Fibrin consumables commonly run in the low tens of dollars per case against roughly fifty to several hundred dollars for a proprietary plasma kit, but the largest real cost in either workflow is the twenty to forty minutes of clinician and staff time spent on the draw, spin, preparation and delivery.
In which indications is the published evidence strong, and where has adoption outrun the research?
This is where I'd slow you down before you book anything. The confidence you'll hear in a consultation room tracks how long that specialty has been using the product, not how well it has been tested, and in places the gap between those two things is enormous. Worse, the trials being pooled together often aren't testing the same thing at all.
Pooled analyses in this field routinely average biologically distinct products, because spin speed, tube chemistry, platelet dose, leukocyte content, activation method, injection volume and session count all differ between studies, which both dilutes real effects and manufactures apparent ones.
